The user has requested enhancement of the downloaded file.
ThrombHaemost 2007; 98: 464-466
V on Willebrand disease( VWD) is ac ongenital bleeding disorderwhich resultsfrom quantitative or qualitative defects of the vonW illebrand factor (VWF)p roduced by endothelialcells and megakaryocytes. It is the most commonly inheritedbleeding disorderinhumans with published prevalence figuresranging from 3-4per 100,000to1.3% of the population (1) .M ore than 20 subtypes of VWDh aveb een described,a lthough currentc lassification consists of 6d istinctt ypes (2) . Ty pes 1and 3are quantitative VWF defects while the fourtype 2 variantsa re qualitative defects. The underlying genetic lesions and associatedm olecular pathology have beeni dentified in manycases of type 2A,2B, 2M, 2N and type 3VWD.However, in the most common variant,type 1VWD,the causative molecular defect is unknown in alarge majority of cases (3) (4) (5) , buthas been addressedrecently by twolarge multi center studies (6, 7) .
The gene encoding VWFislocated on the shortarm of chromosome12(12p13.3), consists of 52 exons and is approximately 178kb kb in length. The signal peptide and propeptide (VW antigenII) are encoded by 16 exons (approximately80kb), while the matures ubunit of VWFa nd 3' non-coding region aree ncodedby35exons in the remaining 100 kb of the gene (8) .Exon 1isuntranslated.
The mature VWFprotein consistsofdifferent domains which are involved in multimerisation, and binding to heparin, clotting factor VIII (FVIII), glycoproteinIb(GpIb), collagen, and glycoprotein IIb/IIIa (GpIIb/IIIa) (9) .
Ty pe 1VWD (60-80%o fa ll VWDc ases)i saquantitative defect( heterozygous for the defective gene)o ften without overtlyi mpaired clotting, with most patients usually leading a relativelyn ormal life. Complications maya rise in the formo f bleeding followings urgery( includingd ental procedures), noticeable easybruising,and/or menorrhagia. Decreased levels of VWFare detected (10-45% of normal). In type 3VWD patients (homozygous for the defective gene)thereisanalmost totalabsenceofVWF and,correspondingly, alow levelofFVIII. These patients maypresentwith severe mucosalbleeding and spontaneous haemarthroses similar to patients with haemophilia (10, 11) .
Asix-year-old male child (FB) of Turkish originpresentedat the outpatient department becauseo fe asyb ruising.Therew as no clear familyhistoryofanobvious bleeding tendency. The parents(fatherEB, motherSB) were consanguineous:first cousins, the issue of brothers.
In this child (FB) VWF:Ag (Elisa) wasundetectable(<1%) withcollagen binding activity <2%, VWF:RCo <1%and FVIII at 1%, whichled to the phenotypic diagnosis of atype 3VWD. On multimer analysis onlyat inys ignali nt he region of the protomer wasdetectable (Fig. 1) .Later in the year the patient returnedwith recurrent haemarthrosis of the left ankle after trauma and wasput on prophylactic treatment threethriceweeklywith FVIII/VWF concentrate (Haemate-P ® ,C LS Behring,B ern, Switzerland).
Laboratorytesting of both parents(EB and SB) showed levelsofVWF:Ag at 56%and 40%, VWF:RCoat38% and 36% and FVIII levels of 73% and 64%, respectively( Table1 ). Neither parent had ahistoryofsevere bleeding problems. Atentativediagnosis of VWDtype 1was made in both parentsand also in one other child (HaB), while the thirdc hild wasn ormal (HyB). Multimer analysis of both parents and the twosiblings of the patient showedanormal patternwith presence of the high-molecular-weight multimers and the typical triplets tructure ( Fig. 1) . The findings were discussed with the parentsand,with informed consent, moleculars tudiesw ere carried outi na ll family members to clarify the diagnosis.
Forthe sequencing of the gene,the VWFcDNAnucleotides arenumbered from the Aofthe initiator AT Gsite as +1. Amino acidresiduesare numbered from the AT Ginitiation codon (residue 1) to the carboxy-terminallysine (residue 2813) of pre-pro-VWF. Correspondence with residues in the matureV WF sequenceisobtained by subtracting 763 from the residuenumber of pre-pro-VWF.H igh-molecular-weightg enomic DNAw as prepared fromleukocytebuffy coats by standard techniquesand wasusedfor the amplification of VWFcoding exons 2through 52 by PCR as previously described (12) . PCRproductswere sequenced by the "ABI Prism Big DyeTerminator Cycle Sequencing Ready Reaction Kit" on an ABIPrism 310(ABI, Foster City, CA, USA). Candidate mutations were confirmed by sequencing both strands.
By analysing the completec oding sequence of the VWF gene,including 51 exons and the exon-intron boundaries acandidates plice sitem utation 0874+1G>Aa ccording to ISTH-SSC-VWF nomenclature (13) (IVS7+1G>Aa ccording to HumanG ene NomenclatureW orking Group [14] )c ould be identified in intron 7for whichthe patient FB provedhomozygous, with both parents (EB and SB)a nd anotherc hild (HaB) heterozygous, while the thirdchild (HyB) provedtobehomozygous wild type. No other mutations could be identified,and there wasnoevidencefor the presenceofaco-existing mutation in the FVIII gene.
In-silicoa nalysis by the splices ite prediction programme (NetGene2 URL: http://www.cbs.dtu.dk/services/NetGene2) predictsthe loss of the original donor splice site, since the original probability scoreof0.97 wasreduced to nil after introducing the respective base exchange. Exon 7skipping could be the possible consequenceof0874+1G>A. This would result in aframeshift, generation of anonsense codon at position 456 in exon 12 and subsequentlywith eitheraseverelytruncated protein with no VWFf unction or with an unstable RNAd ue to nonsense mediated decay.However,due to the lackofpatient'sRNA we could not experimentallyc onfirmt he pathogenic mechanism of this mutant.
Mutations that destroyo rc reate mRNAs plice sites area ssociatedw ith variable severity of disease; this very muchd epends on whether some correct transcriptsc an be processed (mild to moderate disease) or whether there is acomplete loss of correct mRNA processing (severe disease). In ourc aset he homozygous candidate splice sitemutation is linked to asevere phenotype.Heterozygosity for this mutation seemstolead to a quantitative reduction in plasma VWFwith conservation of the normalmultimeric patternresulting in amild type 1VWD with fewbleeding symptoms. In viewofthe mildbleeding symptoms most heterozygous carriers of this mutation mayn ot be diagnosed as having VWDt ype 1, as wast he case in our patient family. The discussion concerning the classification of these kind of patients as having VWD type 1orsimplylow VWF is still ungoing in the literature ( 15, 16) . The presenceo ft he 0874+1G>Amutation in intron 7ofthe VWFgene mayonlylead to the formaldiagnosis of ableeding disorderwhen ahomozygous patient arises. To our knowledge,0 874+1G>Ai san ovel candidate splicesite mutation whichhas notbeen reportedbefore in the literature or in the ISTH-SSC-VWF databaseregistry of known VWDmutations. 
